Epitope-level precision is unlocking new frontiers in drug discovery.

At Kataba Therapeutics, we engineer tailor-made biologics that precisely engage disease-driving proteins, to modulate or inhibit pathogenic variants with unmatched specificity.

By leveraging advanced protein engineering techniques, we:

  • Engage cryptic epitopes inaccessible to traditional biologics
  • Identify functional bispecific configurations
  • Develop active, conditional binders for highly selective therapies

We’re rewriting the rules of drug discovery, and unlocking an entirely new class of therapeutics – smaller, smarter, and built for impact.

Learn More →

Founder PROFILE
Eric Miller

Eric Miller, PhD

Founder / CEO

Dr. Miller earned his PhD in Chemical Engineering from MIT in 2019 and has over a decade of experience in developing minimalist antibody mimetics. He specializes in agile protein engineering, applying efficient design principles and rapid iteration to accelerate therapeutic discovery. His work focuses on higher-order functional selection strategies, enabling the precise development of next-generation biologics.

The therapeutic status quo is changing.

And at Kataba, we're not just adapting - we’re leading the transformation.